eShowcase: Business Services Dashboard
Outsourcing and trial management tool puts professionals in control of all aspects of a study
Outsourcing and trial management tool puts professionals in control of all aspects of a study
EquaTerra (Houston, TX) released an outsourcing and business process management and governance solution based on Microsoft business intelligence technology. Designed to help manage the complexity of blended outsourcing, offshoring, and internal shared services, the comprehensive governance tool provides an enterprise-wide view, enabling plug-ins for other business process intelligence and outsourcing management tools.
The Business Services Dashboard helps organizations derive all the possible value from their business process transformation initiatives. The dashboard solution allows users to view the current status of each business process, along with measurement and management of provider performance. The new product provides drill-down details in six critical business process governance areas: financial management, issue management, contract management, performance management, compliance management, and relationship management.
EquaTerra, (713) 669-9292, www.equaterra.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
